IPTACOPAN ASH UPDATE

Iptacopan is a first-in-class, oral, selective factor B inhibitor of the alternative complement pathway ◉ Dysregulation of the complement pathway is associated with a range of rare hematologic and renal diseases As a selective factor B inhibitor, iptacopan targets the complement system proximally via the alternative pathway, leaving classical and lectin pathway signaling intact Discovered in-house at NIBR 4 IPTACOPAN ASH UPDATE | DECEMBER 13, 2022 NOVARTIS | Reimagining Medicine

View entire presentation